FAAH rs324420 Polymorphism in People With Opioid and Methamphetamine Use Disorders: Psychological Associations
Brain and Behavior · 2026
DOI: 10.1002/brb3.71477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2026. Verfasst von Özlem Erekli-Arat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Forensic Sciences, Ankara University, Ankara, Türkiye. Hauptthemen laut MEDLINE: Amidohydrolases, Amphetamine-Related Disorders, Opioid-Related Disorders. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ankara University Scientific Research Projects Coordination Unit.
Abstract (Originalsprache)
Purpose
The global increase in the prevalence of substance use disorders (SUD) has resulted in higher mortality rates. While heroin use has decreased or stabilized, methamphetamine use is increasing, and the combined use of opioids and methamphetamine is becoming more common. FAAH is an enzyme that hydrolyzes endocannabinoid substances and plays a role in neurobehavioral processes. The aim of this study was to investigate the effect of the FAAH rs324420 polymorphism on SUD.
Method
The study included 562 individuals who used methamphetamine (MUD, n = 148), opioids (OUD, n = 114), or both methamphetamine and opioids (OMCU, n = 150), as well as 150 healthy volunteers. The FAAH rs324420 polymorphism was analyzed by PCR‐RFLP. All participants completed the Barratt Impulsiveness Scale‐11 (BIS‐11), Clinical Opiate Withdrawal Scale (COWS), Substance Craving Scale (SCS), Beck Anxiety Inventory (BAI), and Beck Depression Inventory‐II (BDI‐II). Finding The frequencies of the variant allele (A) were 21%, 13%, 16%, and 19% in OUD, MUD, OMCU, and controls, respectively. Genotype frequencies in all four groups were in Hardy–Weinberg equilibrium ( p > 0.05). The CA genotype significantly reduced the risk of the disease compared to the reference genotype (OR = 0.578, 95% CI:0.343–0.973, adjusted p = 0.039). Craving scale score was higher in individuals who concurrently used opioids and methamphetamine (20.0; 13.0–28.0) than in those who only used opioids (18.0; 14.0–28.0) ( p = 0.009).
Conclusion
This study showed that the rs324420 CA genotype of the FAAH gene may confer a protective effect against methamphetamine use disorder. Future studies with larger sample sizes and additional phenotypic traits are recommended to further explore these findings in other populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Forensic Sciences, Ankara University, Ankara, Türkiye.
- Faculty of Science and Art, Department of Molecular Biology and Genetics, Kırşehir Ahi Evran University, Kırşehir, Türkiye.
- Ankara Training and Research Hospital AMATEM Clinic, Ankara, Türkiye.
ORCID-Profile: Özlem Erekli-Arat, Meltem Tepe, Selin Özkan-Kotiloğlu, Mustafa Danışman, Dilek Kaya-Akyüzlü
Förderung
- Ankara University Scientific Research Projects Coordination Unit
Zitieren
APA
Erekli-Arat, Ö., Tepe, M., Özkan-Kotiloğlu, S., Danışman, M., & Kaya-Akyüzlü, D. (2026). FAAH rs324420 Polymorphism in People With Opioid and Methamphetamine Use Disorders: Psychological Associations. Brain and Behavior. https://doi.org/10.1002/brb3.71477
Vancouver
Erekli-Arat Ö, Tepe M, Özkan-Kotiloğlu S, Danışman M, Kaya-Akyüzlü D. FAAH rs324420 Polymorphism in People With Opioid and Methamphetamine Use Disorders: Psychological Associations. Brain and Behavior. 2026. doi:10.1002/brb3.71477
BibTeX
@article{ErekliArat2026,
author = {Erekli-Arat, Özlem and Tepe, Meltem and Özkan-Kotiloğlu, Selin and Danışman, Mustafa and Kaya-Akyüzlü, Dilek},
title = {FAAH rs324420 Polymorphism in People With Opioid and Methamphetamine Use Disorders: Psychological Associations},
journal = {Brain and Behavior},
year = {2026},
doi = {10.1002/brb3.71477}
}
EUVIMED